We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+1.82%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$330M
AUM Growth
-$23.6M
Cap. Flow
-$25.7M
Cap. Flow %
-7.79%
Top 10 Hldgs %
34.6%
Holding
110
New
18
Increased
26
Reduced
40
Closed
25

Top Buys

Rank Stock Value
1
SBRA icon
Sabra Healthcare REIT
SBRA
+$12.6M
2
DHR icon
Danaher
DHR
+$11.5M
3
MD icon
Pediatrix Medical
MD
+$8.38M
4
JNJ icon
Johnson & Johnson
JNJ
+$7.49M
5
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$5.94M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$8.41M
2
UNH icon
UnitedHealth
UNH
+$6.51M
3
BCR
CR Bard Inc.
BCR
+$6.28M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.22M
5
TMO icon
Thermo Fisher Scientific
TMO
+$5.98M

Sector Composition

Rank Sector Weight
1 Healthcare 82.72%
2 Real Estate 3.7%
3 Financials 2.96%
4 Industrials 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XRAY icon
76
Dentsply Sirona
XRAY
$2.68B
$616K 0.19%
10,300
-87,100
-89% -$5.18M
IMGN
77
DELISTED
Immunogen Inc
IMGN
$601K 0.18%
78,500
-26,000
-25% -$173K
XBI icon
78
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$545K 0.17%
6,300
+3,000
+91% +$241K
CNC icon
79
Centene
CNC
$30.7B
$523K 0.16%
10,800
-43,352
-80% -$1.87M
LCI
80
DELISTED
Lannett Company, Inc.
LCI
$517K 0.16%
+7,000
New +$514K
RDUS
81
DELISTED
Radius Health, Inc.
RDUS
$405K 0.12%
10,500
-12,900
-55% -$506K
LUMO
82
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$367K 0.11%
4,011
-5,389
-57% -$413K
TEVA icon
83
Teva Pharmaceuticals
TEVA
$40.8B
$319K 0.1%
18,133
-44,700
-71% -$1.01M
CBIO
84
Crescent Biopharma
CBIO
$537M
$246K 0.07%
176
-143
-45% -$168K
A icon
85
Agilent Technologies
A
$39.1B
– –
-8,600
Closed -$510K
BKD icon
86
Brookdale Senior Living
BKD
$3.49B
– –
-126,500
Closed -$1.86M
BMRN icon
87
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-9,300
Closed -$845K
CNMD icon
88
CONMED
CNMD
$1.39B
– –
-18,700
Closed -$953K
CRL icon
89
Charles River Laboratories
CRL
$11.2B
– –
-28,248
Closed -$2.86M
EXEL icon
90
Exelixis
EXEL
$13.3B
– –
-15,870
Closed -$391K
FOLD
91
DELISTED
Amicus Therapeutics
FOLD
– –
-118,800
Closed -$1.57M
GSK icon
92
GSK
GSK
$104B
– –
-34,800
Closed -$1.88M
HUM icon
93
Humana
HUM
$43.7B
– –
-4,000
Closed -$962K
ILMN icon
94
Illumina
ILMN
$31B
– –
-9,046
Closed -$1.53M
LH icon
95
Labcorp
LH
$25B
– –
-8,395
Closed -$1.11M
LLY icon
96
Eli Lilly
LLY
$1.02T
– –
-9,600
Closed -$790K
OFIX icon
97
Orthofix Medical
OFIX
$477M
– –
-30,400
Closed -$1.41M
RGNX icon
98
Regenxbio
RGNX
$620M
– –
-36,000
Closed -$711K
RVTY icon
99
Revvity
RVTY
$12.6B
– –
-24,400
Closed -$1.66M
NUVA
100
DELISTED
NuVasive, Inc.
NUVA
– –
-27,800
Closed -$2.14M
1 2 3
4
5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Endurant Capital Management held 110 positions worth $330M, down 6.7% from $354M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Endurant Capital Management withdrew a net $25.7M in Q3 2017, closing 25 positions and reducing 40 holdings. Its most notable exit was K2M Group Holdings, Inc, an estimated $3.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 88% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Endurant Capital Management opened a new position in Sabra Healthcare REIT worth $12.2M.

  • Endurant Capital Management's largest Q3 2017 buy was Sabra Healthcare REIT: 556,330 shares worth $12.2M.
  • Endurant Capital Management added most to Tivity Health, Inc. Common Stock in Q3 2017, an estimated $5.94M increase.
  • Endurant Capital Management's biggest Q3 2017 reduction was Becton Dickinson, cutting an estimated $8.41M.
  • Endurant Capital Management fully exited K2M Group Holdings, Inc in Q3 2017, selling an estimated $3.4M.
  • Endurant Capital Management's ten largest holdings make up 35% of its $330M portfolio in Q3 2017.
  • Endurant Capital Management opened 18 new positions and closed 25 in Q3 2017.
  • Endurant Capital Management's portfolio value fell 6.7% quarter-over-quarter to $330M.

Based on Endurant Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.